Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 4/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807251 | 0.86 | TRPC5 (0.44) | TRPC5PARP1TNKS2PARP2P2RX7 | |
| SCHEMBL21807309 | 0.81 | PARP1 (0.43) | TRPC5PARP1TNKS2PARP2P2RX7 | |
| SCHEMBL21807357 | 0.78 | TRPC5 (0.51) | TRPC5PARP1TNKS2PARP2P2RX7 | |
| SCHEMBL21807333 | 0.76 | P2RX7 (0.47) | TRPC5P2RX7 | |
| SCHEMBL22413405 | 0.74 | TRPC5 (0.42) | TRPC5PARP1TNKS2PARP2RORC | |
| SCHEMBL21807166 | 0.72 | TRPC5 (0.43) | TRPC5PARP1TNKS2PARP2P2RX7 | |
| SCHEMBL25324925 | 0.71 | P2RX3 (0.47) | PARP1TNKS2PARP2P2RX3PDE10A | |
| SCHEMBL21807467 | 0.70 | P2RX7 (0.42) | TRPC5P2RX7TRPV1PDE10A | |
| SCHEMBL21807275 | 0.70 | PARP1 (0.37) | TRPC5PARP1TNKS2PARP2P2RX7 | |
| SCHEMBL21807252 | 0.69 | PARP1 (0.40) | TRPC5PARP1TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | TRPC5 3626/4885PARP1 3410/4885TNKS2 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.